Aronin also said the company set the price at $89,000 based on resources it invested to bring the drug to market and complete clinical studies. He said the funds would also be used to pay for future research and ensure broad patient access through insurer reimbursement and its own assistance programs. Marathon did not develop the drug but had to get FDA approval for the drug before it could be widely available in the U.S. The company now will have exclusive rights to sell the drug in the U.S. for seven years.